Quantcast

Occlutech Obtains CE Mark for the new Generation PFO & ASD Occluders

May 12, 2009

JENA, Germany, May 12 /PRNewswire/ — Occlutech, the leading European
developer of septum occluders, today announced that it has obtained CE mark
approval for its new generation ASD and PFO occluders, the Figulla Flex.

The Figulla Flex ASD and PFO occluders encompass a new innovative
delivery system, making the use of a threaded hub unnecessary. The
implantation of the occluder is facilitated by the ability of the delivery
system to allow a 45 degree angle before release.

The Occlutech Figulla Flex will be exhibited and demonstrated at the PCR
vascular intervention meeting in Barcelona from May 19th to May 22nd.

Occlusion devices are used to treat structural heart disease, including
structural heart defects and abnormalities such as Atrial Septal Defects,
(ASD), and Patent Foramen Ovale (PFO, an undesired channel between the
heart’s two atria, present in up to 25% of the population), in minimally
invasive, non-surgical procedures. The market for PFO occluders is expected
to expand significantly as the link between PFO and stroke, that is the third
most common cause of death, as well as severe migraine becomes increasingly
well documented.

    Contact:

    Tor Peters
    info@occlutech.de
    Tel: +49-3641-67-51-29

    Katrin Biedermann
    katrin.biedermann@occlutech.de
    Tel.: +49-3641-67-51-20

SOURCE Occlutech GmbH


Source: newswire



comments powered by Disqus